Replimune Group, Inc. (NASDAQ:REPL) Receives Average Recommendation of “Moderate Buy” from Analysts

Replimune Group, Inc. (NASDAQ:REPL) has been given an average recommendation of “Moderate Buy” by the eleven brokerages that are covering the stock, Marketbeat.com reports. Two investment analysts have rated the stock with a sell recommendation, two have given a hold recommendation, six have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is $9.75.

A number of research firms have recently commented on REPL. Leerink Partnrs upgraded Replimune Group from a “hold” rating to a “strong-buy” rating in a research report on Monday, October 20th. Leerink Partners upgraded Replimune Group from a “market perform” rating to an “outperform” rating and raised their price target for the stock from $3.00 to $13.00 in a research note on Monday, October 20th. HC Wainwright raised Replimune Group from a “neutral” rating to a “buy” rating and set a $12.00 price target on the stock in a research report on Monday, October 27th. Piper Sandler raised Replimune Group from a “neutral” rating to an “overweight” rating and set a $13.00 price objective for the company in a report on Monday, October 20th. Finally, JPMorgan Chase & Co. raised shares of Replimune Group from an “underweight” rating to a “neutral” rating and set a $11.00 target price on the stock in a report on Monday, October 20th.

Replimune Group Stock Down 0.4%

Shares of NASDAQ:REPL traded down $0.04 during trading on Friday, hitting $10.02. 855,213 shares of the company were exchanged, compared to its average volume of 2,183,934. The firm’s 50 day moving average price is $7.26 and its 200-day moving average price is $7.48. Replimune Group has a 12-month low of $2.68 and a 12-month high of $14.80. The company has a debt-to-equity ratio of 0.26, a current ratio of 6.31 and a quick ratio of 6.31. The stock has a market capitalization of $786.28 million, a P/E ratio of -2.90 and a beta of 0.80.

Replimune Group (NASDAQ:REPL) last announced its quarterly earnings results on Thursday, November 6th. The company reported ($0.90) EPS for the quarter, missing the consensus estimate of ($0.87) by ($0.03). On average, research analysts predict that Replimune Group will post -2.97 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, insider Christopher Sarchi sold 5,208 shares of the company’s stock in a transaction dated Monday, November 17th. The shares were sold at an average price of $9.10, for a total value of $47,392.80. Following the completion of the sale, the insider directly owned 123,088 shares of the company’s stock, valued at approximately $1,120,100.80. This represents a 4.06% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Konstantinos Xynos sold 7,248 shares of the business’s stock in a transaction dated Monday, November 17th. The shares were sold at an average price of $9.10, for a total value of $65,956.80. Following the completion of the transaction, the insider owned 139,685 shares in the company, valued at $1,271,133.50. This trade represents a 4.93% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 5.20% of the company’s stock.

Institutional Investors Weigh In On Replimune Group

Large investors have recently modified their holdings of the stock. Goldman Sachs Group Inc. raised its position in Replimune Group by 20.9% during the 1st quarter. Goldman Sachs Group Inc. now owns 690,167 shares of the company’s stock worth $6,729,000 after buying an additional 119,145 shares during the last quarter. Exome Asset Management LLC boosted its holdings in shares of Replimune Group by 438.6% in the first quarter. Exome Asset Management LLC now owns 294,846 shares of the company’s stock valued at $2,875,000 after acquiring an additional 240,108 shares in the last quarter. Nuveen LLC acquired a new position in shares of Replimune Group during the first quarter worth about $6,546,000. Deutsche Bank AG increased its stake in shares of Replimune Group by 0.4% during the first quarter. Deutsche Bank AG now owns 563,701 shares of the company’s stock worth $5,496,000 after acquiring an additional 2,140 shares during the period. Finally, Bank of New York Mellon Corp raised its holdings in Replimune Group by 8.4% during the first quarter. Bank of New York Mellon Corp now owns 189,177 shares of the company’s stock worth $1,844,000 after purchasing an additional 14,659 shares in the last quarter. Hedge funds and other institutional investors own 92.53% of the company’s stock.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.